Hepatitis B Virus Services

Novel Multi-Marker Screening Platform

ImQuest has developed a multi-parameter microtiter assay to expedite the screening of antiviral agents against multiple markers of hepatitis B virus (HBV) replication and to gain insight into mechanism of action. The assay can be customized to meet your development needs.
The multi-marker assay has been optimized for standard cell lines -- HepG2 2.2.15, Hep AD38, Hep AD79, and hNTCP -- and also for primary human hepatocytes (PHH). PHH have been pre-screened for their ability to support HBV infection and replication. Cryoplateable PHH are available and all PHH lots are tested for viable infection prior to use at variable MOIs.* These assay can be utilized for traditional small molecule therapeutics and biologics, modified for neutralization based assays and antibody based therapeutics, and used to asses the effects of CRISPR based therapeutic applications.

Numerous qPCR and ELISA-based endpoints are currently available including quantification of the following:

  • Extracellular HBV DNA
  • Intracellular HBV DNA
  • cccDNA
  • Pre-genomic RNA
  • Protein-based endpoints: HBsAg, HBeAg, HBcAg

Our suite of anti-HBV services includes assays to evaluate range of action, time of addition assessment, efficacy in drug combinations, potential for resistance, characterization of resistant strains and effect of serum binding effects. Contact us to request a quote for HBV Services.

Primary Human Hepatocyte Screening

ImQuest has developed a robust and reproducible microtiter based screening assay using Primary Human Hepatocytes (PHH). While the stable-cell line assay remains a reliable and robust assay for screening, using chronically infected cells prevents the assessment of agents that inhibit the early stages of viral infection (entry, un-coating and cccDNA formation). Infected PHH can be used to screen for antiviral compounds targeting multiple markers of HBV infection. Timing of infection and compound addition can be customized and has proved critical to the assessment of HBV infection markers. The PHH system more closely resembles natural HBV infection and remains a gold standard for antiviral agent screening.

To view our white papers and posters on HBV antiviral drug development, click on the links below:

High Titer HBV Virus Stock Production

ImQuest BioSciences provides technical services for the production of high titer and highly infectious HBV virus stocks. We can propagate, concentrate, and characterize HBV at scales ranging from milliters to liters, saving you time and avoiding the tedious steps required for HBV production. Whatever your needs, our scientists will customize the virus production process to your specifications.

Virus Production Services include:

  • Production of crude virus preparations from AD38, HepG2.2.15 and AD79 cell lines
  • Concentration of virus from crude preparations utilizing Tangential Flow Filtration (TFF)
  • Determination of virus concentration by qPCR and TCID50 determinations
  • Preparation of inactivated virus
  • Isolation of viral proteins, RNA & DNA
  • Quantification of proteins and nucleic acids

Documentation of final viral titer is provided with each lot of virus produced. For HBV, we routinely achieve virus concentrations in excess of 5x1010 genome equivalents per milliliter. Infectious virus in each pool may also be quantified by TCID50. Virus can be shipped domestically and internationally, and we are certified for the shipment of Category A and Category B Infectious Substances.

Contact us to request a quote for HBV viral stock production.

*Multiple PHH lots have been screened for their ability to support HBV replication. Cell lots are subject to availability; multiple lots may need to be tested prior to initiation of screening studies. ImQuest BioSciences is a preclinical contract research and development organization (CRO) that provides service to evaluate the potential efficacy of new and novel pharmaceutical products for the treatment and prevention of viruses, bacteria, cancer and inflammatory disease, including in vitro toxicology and product formulation services.